Scientific editorial illustration of a glowing mitochondrial TCA cycle, calcium-mineral crystals and DNA methylation tags for a Ca-AKG evidence review
Geroprotect Blog

Geroprotect research note · Evidence review

Ca-AKG: From the TCA Cycle to the Epigenetic Clock

Metabolic and epigenetic mechanisms, limited human clock data, mixed mouse lifespan results and the 450 mg formula boundary

Abstract

Calcium alpha-ketoglutarate (Ca-AKG) supplies the calcium salt of alpha-ketoglutarate, an endogenous tricarboxylic-acid-cycle intermediate and co-substrate for iron- and 2-oxoglutarate-dependent enzymes. That biology makes Ca-AKG a credible research subject. It does not make oral supplementation an epigenetic reset.

The most quoted human result—an average 7.96-year decrease on a proprietary saliva DNA-methylation clock—came from a retrospective analysis of 42 customers taking a commercial delayed-release Ca-AKG-plus-vitamin product. It had no placebo group, tested a combination rather than Ca-AKG alone, and did not measure healthspan, disease or survival. A 2026 cross-sectional study found a smaller association in 143 self-reported users of the same branded combination, but its longitudinal Ca-AKG analysis was not significant. The randomized ABLE trial has completed its primary intervention period, but no results are posted as of 14 July 2026. Mouse lifespan findings are also mixed: a positive 2020 study in C57BL/6 mice was followed by two null multisite tests in genetically heterogeneous mice. Geroprotect Essentials I contains 450 mg of Ca-AKG per full six-tablet labelled serving; no study has tested that amount, Essentials I, or both Geroprotect formulas for epigenetic age, frailty or lifespan.

01 · Identity and mechanism

A metabolic intermediate with several different jobs

Alpha-ketoglutarate—also called 2-oxoglutarate or 2-OG—is a five-carbon intermediate in the TCA cycle. Cells can produce it from isocitrate and from glutamate-linked reactions, then consume it through alpha-ketoglutarate dehydrogenase to form succinyl-CoA. “Ca-AKG” identifies a calcium salt; it does not, by itself, establish a sustained-release formulation, superior human bioavailability or a particular blood-exposure profile.

AKG is also a co-substrate for iron- and 2-oxoglutarate-dependent dioxygenases. These include TET enzymes that oxidise methylated cytosines, JmjC-domain histone demethylases, oxygen-sensing prolyl hydroxylases and collagen hydroxylases. Their core reaction uses AKG, molecular oxygen and enzyme-bound ferrous iron, producing succinate and carbon dioxide.10

This establishes biochemical participation, not oral rate limitation. A cell can be constrained by enzyme abundance, oxygen, iron handling, competing metabolites, substrate access or compartmentalisation. No human study has shown that 450 mg of oral Ca-AKG reaches a target tissue, increases TET flux there and thereby improves a clinical outcome.

What TET biology does—and does not—say about epigenetic clocks

TET enzymes oxidise 5-methylcytosine to forms that can enter active or replication-linked demethylation pathways. In mouse embryonic stem cells, vitamin C increased TET activity and changed DNA methylation.11 That experiment did not give Ca-AKG to people. Epigenetic clocks also combine methylation values that move in different directions at selected sites; they are not a meter of global demethylation. A lower clock estimate therefore does not demonstrate TET activation, cellular rejuvenation or longer life.

02 · Human clock evidence

One uncontrolled change, one cross-sectional association, one pending randomized answer

The 42-customer Rejuvant analysis

Demidenko and colleagues retrospectively identified 42 self-reported healthy customers who had completed saliva clock tests before and after four to ten months of Rejuvant use. The daily serving supplied 1 g of timed-release Ca-AKG plus vitamin A for men or vitamin D for women. The proprietary TruAge model used nine CpG sites in three genes. Mean estimated methylation age decreased by 7.96 years after an average of seven months.1

The result is a hypothesis-generating within-person change, not proof that Ca-AKG reversed aging. There was no randomized comparison, no placebo, no Ca-AKG-only arm, no independent clock or clinical endpoint, and no way to separate Ca-AKG from the sex-specific vitamins, selection effects, regression to the mean or time. The test provider had a service agreement with the product company; one author was a scientific consultant and board member of that company. The paper itself called for placebo-controlled confirmation.

The 2026 real-world cohort

Pabis and colleagues analysed 4,260 people who had bought a TruMe saliva test and reported lifestyle, medication and supplement use. Among 143 self-declared users of the delayed-release Rejuvant combination, cross-sectional age residual was 1.8 years lower on average; matching on measured covariates yielded a 1.27-year difference. This remained an association in a convenience sample, not a treatment effect. The product still combined Ca-AKG with vitamins, dose and frequency were not collected, and some customers recruited through the manufacturer received test vouchers.2

The longitudinal analysis is an important restraint. Only 26 self-declared delayed-release AKG users had repeat-test data, and their change was not significant. A subscription-based association also became non-significant after adjustment for baseline age residual and regression to the mean. The study used the same proprietary first-generation, nine-CpG clock, and one author was a scientific adviser and board member of the product company. These data support further study; they do not independently replicate an eight-year reversal.

ABLE: the randomized test has not yet reported

ABLE randomised 120 adults aged 40–60 whose DNA-methylation age exceeded chronological age to 1 g/day sustained-release Ca-AKG or placebo for six months, followed by three months of observation. Its primary outcome is change in blood DNA-methylation age; secondary outcomes include physiological and laboratory measures.3 ClinicalTrials.gov lists the study as active, not recruiting, with primary completion on 15 August 2025, estimated study completion on 15 January 2027, and no posted results as of 14 July 2026.4 Until outcomes are published, ABLE is a protocol—not positive evidence.

03 · Controlled human evidence

A bone-turnover signal at a much higher amount

A six-month double-blind trial randomised 76 postmenopausal women with osteopenia to calcium alpha-ketoglutarate supplying 6 g of AKG and 1.68 g of calcium daily, or 1.68 g of calcium alone. Serum CTX, a bone-resorption marker, fell 37% from baseline in the AKG group at 24 weeks, and between-group CTX differences were significant at 12 and 24 weeks. Osteocalcin did not change. Lumbar-spine bone mineral density rose 1.6% from baseline in the AKG group, but the estimated 0.9% difference between groups was not statistically significant.5

This is a genuine randomized human signal, with equally important boundaries: one selected disease-risk population, one surrogate turnover marker, six months, and an AKG amount more than thirteen times the 450 mg listed for Essentials I. It did not test fracture risk, biological aging, healthy adults or Geroprotect. Numerical dose comparison cannot be used to predict a proportional effect.

04 · Preclinical longevity

Compelling first studies met a serious replication test

Worms and pathway discovery

In Caenorhabditis elegans, 8 mM AKG increased lifespan by roughly 50% in the initial screen. Protein-target experiments identified ATP synthase subunit beta; AKG reduced ATP synthase activity, oxygen consumption and TOR signalling and increased autophagy in worms and mammalian cells. AKG did not add lifespan in the study’s dietary-restriction model.9 This supports a pathway in those experimental systems. It does not establish that an oral human serving is a caloric-restriction mimetic.

The positive 2020 mouse study

Two cohorts of C57BL/6 mice began a diet containing 2% Ca-AKG at 18 months. Female median lifespan from treatment onset increased 16.6% in one cohort and 10.5% in the other; corresponding 90th-percentile survival increased 19.7% and 8%. Male survival changes were not significant. Frailty-index area under the curve was 46% lower in females and 41% lower in males.6

The study is important and commercially connected. It was supported in part by Ponce de Leon Health; several authors held shares, board roles or patent interests. The control diet also was not calcium-matched, which the authors identified as a limitation.

Two multisite null tests

The US National Institute on Aging Interventions Testing Program then used genetically heterogeneous UM-HET3 mice at three sites. At the same 20,000-parts-per-million dietary amount and the same 18-month start, AKG changed median lifespan by only 3.0% in males and 0.9% in females; neither result was significant. The treated groups included 153 males and 132 females, with a double-sized control group.7

A second multisite ITP experiment, published in 2026, started the same AKG amount at seven months to test whether earlier exposure would help. Again, lifespan did not increase in either sex.8 Strain, environment and other protocol differences could explain discordance; they cannot be assumed away. The accurate conclusion is mixed mouse evidence, not replicated mammalian lifespan extension.

05 · Cofactors and combinations

Biochemical dependency is not a finished-formula interaction

The source memorandum described vitamin C as an absolute requirement for every AKG-dependent dioxygenase and said Geroprotect supplies vitamin C, iron and a broad vitamin-mineral “companion layer.” Neither statement matches the evidence or current formula.

The conserved dioxygenase reaction fundamentally requires AKG, oxygen and enzyme-bound Fe(II). Ascorbate can preserve or restore activity, and collagen hydroxylases have a strong, specific ascorbate dependence. Across the wider enzyme family, however, dependence varies; the 2025 mechanistic review explicitly notes that the core reaction has no universal fundamental ascorbate requirement and that enzyme context, pH and uncoupled reactions affect the measured need.10

The current 13-plus-13 Geroprotect formula does not list vitamin C, iron, thiamine, riboflavin, pantothenate, vitamin B6, lipoic acid, zinc or magnesium as actives. It would therefore be inaccurate to market Essentials I and II as a complete AKG cofactor system. It would also be unsafe to advise adding iron solely from this pathway diagram; iron supplementation belongs to individual clinical assessment.

Essentials I does contain other metabolites and polyphenols that touch interconnected pathways, but no component-controlled human trial has shown that Ca-AKG works better with NMN, 5-ALA, Coenzyme Q10, Spermidine, Apigenin or any other formula ingredient. Network proximity can justify a research question. It cannot establish additivity, synergy, tissue exposure or a clinical benefit.

06 · Safety and interpretation

An endogenous molecule still needs product-level evidence

The fact that humans produce AKG does not by itself establish the safety of a concentrated oral calcium salt. The 42-customer Rejuvant paper was not designed to estimate adverse-event rates, the 2026 cohort relied on self-reported use without dose, and the bone trial followed 76 women for six months. Together they leave long-term safety in healthy, broadly representative adults incompletely characterised.

Ca-AKG also contributes calcium, but the amount of elemental calcium depends on the exact material specification. The current public formula names 450 mg of Ca-AKG, not 450 mg of elemental calcium. People with kidney disease, recurrent calcium-containing stones, abnormal calcium regulation, pregnancy or breastfeeding, or medicines that materially affect calcium or renal handling should use individual clinical guidance. These are context precautions, not evidence that adverse effects are common at the Geroprotect amount.

No reviewed study establishes a special fasted timing window, cycling schedule, taper or 1–3 g “longevity dose.” This article therefore does not turn experimental amounts into a self-dosing protocol.

07 · Formula context

What 450 mg in Essentials I does—and does not—mean

A full six-tablet labelled serving of Geroprotect Essentials I contains 450 mg of Ca-AKG. That is below the 1 g/day used in Rejuvant and ABLE and far below the 6 g/day of AKG used in the osteopenia trial. A lower amount is not automatically ineffective, safer or bioequivalent; the relevant exposure, delivery matrix and target outcome have not been established.

No trial has tested 450 mg of Ca-AKG for a validated human aging outcome. No trial has tested Essentials I, both Geroprotect formulas, or their proposed epigenetic and mitochondrial interactions. The current public certificate archive also does not yet establish a current finished-batch link, elemental-calcium contribution, sustained-release profile or human pharmacokinetic equivalence to Rejuvant or ABLE.

StatementEvidence boundary
AKG is a TCA-cycle intermediate and dioxygenase co-substrateEstablished biochemistry.
Ca-AKG reversed human biological age by eight yearsNot established. An uncontrolled commercial combination study changed one proprietary clock estimate.
Ca-AKG extends mammalian lifespanMixed. One C57BL/6 study was positive in females; two multisite UM-HET3 studies were null.
Vitamin C and iron make the Geroprotect stack completeIncorrect for the current formula; neither vitamin C nor iron is listed among the 26 actives.
Essentials I improves epigenetic agingUnproven. No finished-formula trial has measured that outcome.

Questions

Frequently asked questions

What is Ca-AKG?

It is a calcium salt of alpha-ketoglutarate, an endogenous TCA-cycle intermediate also used as a co-substrate by several enzyme families. The salt identity alone does not prove sustained release or superior bioavailability.

Did Ca-AKG reverse biological age by eight years?

No controlled trial has shown that. The number came from a 42-customer, uncontrolled before-and-after analysis of Ca-AKG plus sex-specific vitamins using a proprietary nine-CpG saliva clock. It is a signal to test, not evidence of age reversal.

Has the ABLE randomized trial reported results?

No results were posted on ClinicalTrials.gov as of 14 July 2026. The record lists primary completion in August 2025 and estimated overall completion in January 2027.

Does Ca-AKG extend lifespan in mice?

The answer is mixed. One study in C57BL/6 mice found significant female lifespan extension and lower frailty in both sexes. The NIA Interventions Testing Program found no lifespan extension in genetically heterogeneous mice when the same dietary amount began at either 18 or seven months.

Does Ca-AKG need vitamin C and iron?

AKG-dependent dioxygenases use iron, oxygen and AKG; ascorbate supports several family members and is especially important for collagen hydroxylases, but dependence varies. This mechanism is not a reason to self-prescribe iron. Vitamin C and iron are not listed actives in the current Geroprotect formulas.

Is 450 mg an evidence-backed longevity dose?

No. It is the current labelled amount in Essentials I. The human studies reviewed used different products and higher amounts for clock or bone-turnover outcomes; none established a human longevity dose.

Has the Geroprotect formula been tested with Ca-AKG?

No completed human trial has tested Essentials I, the combined formulas or their proposed ingredient interactions for epigenetic age, frailty, healthspan or lifespan.

Sources

References

  1. Demidenko O, et al. Rejuvant, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging. Aging. 2021;13:24485–24499. DOI 10.18632/aging.203736.
  2. Pabis K, et al. Supplements and drugs are associated with biological age in a cohort of exceptionally healthy individuals. Aging Cell. 2026;25:e70517. DOI 10.1111/acel.70517.
  3. Sandalova E, et al. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol. GeroScience. 2023;45:2897–2907. DOI 10.1007/s11357-023-00813-6.
  4. National Library of Medicine. ABLE study record: NCT05706389. ClinicalTrials.gov. Record updated 26 May 2026; accessed 14 July 2026.
  5. Filip RS, et al. Alpha-ketoglutarate decreases serum levels of C-terminal cross-linking telopeptide of type I collagen in postmenopausal women with osteopenia: six-month study. International Journal for Vitamin and Nutrition Research. 2007;77:89–97. DOI 10.1024/0300-9831.77.2.89.
  6. Asadi Shahmirzadi A, et al. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. Cell Metabolism. 2020;32:447–456.e6. DOI 10.1016/j.cmet.2020.08.004.
  7. Miller RA, et al. Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin. GeroScience. 2024;46:4657–4670. DOI 10.1007/s11357-024-01176-2.
  8. Korstanje R, et al. Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan in UM-HET3 mice. GeroScience. 2026;48:3821–3830. DOI 10.1007/s11357-026-02201-2.
  9. Chin RM, et al. The metabolite alpha-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature. 2014;510:397–401. DOI 10.1038/nature13264.
  10. Smith-Díaz CC, et al. Exploring the ascorbate requirement of the 2-oxoglutarate-dependent dioxygenases. Journal of Medicinal Chemistry. 2025;68:2219–2237. DOI 10.1021/acs.jmedchem.4c02342.
  11. Blaschke K, et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in embryonic stem cells. Nature. 2013;500:222–226. DOI 10.1038/nature12362.

Quality you can check

Every badge links to the document behind it: manufacturer certificates, certificates of analysis for all 26 actives, and our own promises about the formula.

Huazhen Biotechnology (Shenzhen) holds ISO 22000:2018 certificate 015FSMS2400550 and HACCP certificate 015HACCP2400460, both valid until 2 December 2027. These are manufacturer system papers, not a product certificate. The earlier papers 150FSMS2200001 and 150HACCP2200001 ended in March 2025 and are not shown as valid. Halal certificates cover raw materials from our suppliers; Geroprotect Essentials is not registered as a halal product. Food supplement. Read the current product label before use.

Bought from Geroprotect? Leave an honest review:Review us on TrustpilotReview us on GoogleReview on Amazon.aeReviews are optional and never rewarded. More about reviews.
Scroll to Top